Almac
announced today that its Clinical Technologies division has moved into the Almac Group’s new North American Headquarters. After groundbreaking of the 40-acre site in Souderton, PA on Juy 23, 2008, the drug development firm has now completed the first phase of relocating employees from three Almac business units to the new 240,000 square feet state-of-the-art integrated drug development facility.
On October 11, Almac’s technology business unit joined employees from Almac’s analytical testing and clinical supplies units as occupants at the North American Headquarters. Over the course of the next two months, Almac will transition the remainder of its clinical supplies operations currently located in Audubon, PA, into the integrated drug development facility in Souderton, PA.
The transition of the technologies business into Almac’s new North American Headquarters was carefully planned and executed. Over the course of the past few months, Almac successfully relocated and tested all of its new and existing technologies and systems in the new locale to make certain that there were no disruptions to client studies during the transition into the North American Headquarters.
Jim Murphy, President of Almac’s clinical technologies business unit, comments on the move of the business from Yardley, PA, to its new location in Souderton, PA. Murphy: “Our IT, Quality Assurance, senior management team, and other key personnel worked in unison to ensure that all of our systems were tested and met the highest standards before we moved into the new facility. The transition team’s meticulous planning enabled us to avoid any downtime on client studies outside of our normal maintenance windows.”
The move of three Almac business units to a new North American Headquarters is part of the Almac Group’s integrated services solutions strategy. The new facility was planned to deliver a full-service, integrated drug supply management and technology solution to biopharmaceutical clients.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.